Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis Followed by an Open-Label Safety Extension

NCT01917019 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT01917019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01917019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis Followed by an Open-Label Safety Extension
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2013
Completion date
March 31, 2017
Enrollment
101 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, multiple sclerosis, primary progressive, multiple sclerosis, remittent progressive, relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis